ISRD & ATS 2016:助力青年医师与国际接轨论文报告会圆满落幕

2016-10-20 MedSci MedSci原创

2016 年10月14日~16日,由中国健康促进基金会、上海市呼吸病研究所、国际呼吸学会等主办,美国胸科协会(ATS)和复旦大学呼吸病研究所等协办,上海梅斯医学承办的“第十二届上海国际呼吸学会暨ATS联合论坛”(ISRD & ATS 2016)在上海展览中心隆重举行。 通过近十二年的努力,ISRD为呼吸病领域的专家、临床研究人员、从业医师以及青年学者提供世界范围最新的行业资讯和研究成

2016年10月14日~16日,由中国健康促进基金会、上海市呼吸病研究所、国际呼吸学会等主办,美国胸科协会(ATS)和复旦大学呼吸病研究所等协办,上海梅斯医学承办的“第十二届上海国际呼吸学会暨ATS联合论坛”(ISRD & ATS 2016)在上海展览中心隆重举行。

通过近十二年的努力,ISRD为呼吸病领域的专家、临床研究人员、从业医师以及青年学者提供世界范围最新的行业资讯和研究成果。超过全球20多个国家和地区的2000余名专业人士每年定期云集ISRD进行学术交流。其影响力和号召力更是不断向欧美扩展,已经成为亚洲最具学术代表性的呼吸病论坛之一。

本次大会凭借“接轨国际新契机,直面名家近距离,启发创新有知音,走向世界助推器”的新理念,10月16日下午16点整,“接轨国际英才”专场隆重举行。本专场由James M. Beck教授,罗远明教授和李志超教授担任主席,苏枭研究员和周建研究员担任评委,共有22位青年医师进行了课题汇报。汇报结束时,共评出一等奖1名,二等奖3名,三等奖5名,其余报告者评为优胜奖(获奖人员名单加下表)。以上讲者均有机会被推荐投稿到2016年ATS大会,并申请International Travel Award。随后,James M. Beck教授和白春学教授分别给获奖者颁奖。


随后,获奖青年医师分别与白春学教授合影留念。至此,ISRD & ATS 2016大会“接轨国际英才”专场圆满结束。


白春学教授与一等奖获得者合影(见上图)


白春学教授与二等奖获得者合影(见上图)


白春学教授与三等奖获得者合影(见上图)


专场嘉宾和青年医师汇报者合影(见上图)



附:“接轨国际英才”专场获奖人员名单

ISRD-ATS Shanghai Award

Score  

1-10(Excellent)

Probability of Cancer in High Risk Patients Predicted by the    Protein-based Lung Cancer Biomarker Panel in China: LCBP study

一等奖

Dawei Yang 杨达伟  复旦大学附属中山医院

Role of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 in Acute Exacerbation of Chronic Obstructive Pulmonary Disease and the Potential Mechanism

二等奖

Yichun Zhu 朱亦淳  复旦大学附属中山医院

miR-26a desensitizes non-small cell lung cancer cells to tyrosine kinase inhibitors by targeting PTPN13

Ning Zhu   朱柠  复旦大学附属华山医院

A Novel approach for Detection of Circulating Tumor Cells by Replication-selective Adenovirus in Lung Cancer   

Xiaole Yang 杨晓乐  郑州大学第一附属医院              

Effects of plasminogen activator inhibitor type-1 on mesenchymal stem cells in LPS-induced acute lung injury

三等奖

Nana Feng  冯娜娜  上海市第一人民医院

Autophagy is Induced by TGF-β1 and Alleviates TGF-β1-Mediated Growth Inhibition in Human Non-Small Cell Lung Cancer Cells

Jian Wang  王坚  复旦大学附属中山医院

Identifying differentially expressed long non-coding RNAs in early stage non-small cell lung cancers

Zule Cheng  程祖乐  中国科学院上海微系统与信息技术研究所

Ruscogenin alleviates lipopolysaccharide-induced pulmonary endothelial barrier dysfunction by suppressing intercellular adhesion structure disruption

Xiu Yu     余秀  中国药科大学

The critical role of A2AR in the balance of Treg and Th17 cell in allergic asthma

Linlin Wang  王林林 复旦大学附属中山医院

Interventional therapy in sarcoidosis-associated pulmonary arterial stenosis and pulmonary hypertension

优胜奖

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


Xiujuan Zhang 张秀娟  复旦大学附属华山医院

Resistance to EGFR tyrosine kinase inhibitors in a patient with transformation from lung adenocarcinoma to small cell lung cancer

Xia Zhang   张霞  复旦大学附属华山医院

Differences of PKM1, PKM2 and mRNA hnRNPB1 in different pathological types of lung cancer

Yi Gong     龚益  复旦大学附属华山医院

Clinical observation of nimotuzumab combined with chemotherapy as first line therapy for advanced lung squamous cell carcinoma

Xiaoyan Si   斯晓燕  北京协和医院

Dynamic Monitoring of EGFR Mutation in Plasma Cell-Free DNA by Digital PCR

Xiaoxia Cui  崔晓霞  北京协和医院

Congenital Unilateral Pulmonary Vein Atresia in Adults as a Rare Cause of Unilateral Pulmonary Interstitial Changes: A Case and Systemic Literature Review

Hanping Wang  王汉萍  北京协和医院呼吸科

A panel of lncRNA markers for the early detection of lung adenocarcinoma with bronchial brushing specimens

Yanan Bai  白亚楠  中国科学院上海微系统与信息技术研究所

PTEN expression is associated with the outcome of lung cancer: evidence from a meta-analysis

Jincui Gu  谷金萃  中山大学附属第一医院

Performance of parallel diagnostic algorithms based on CYFRA 21-1 for the diagnosis of malignant pleural effusion: a systematic review and meta-analysis

Yan Gu     顾岩  内蒙古医科大学附属医院

Sputum cell sorting in the two Main Types of COPD

Huifang Song 宋慧芳  内蒙古自治区人民医院

The Initial Vision of the Development of Medical Internet of Things in China

Jifeng Hou  侯吉锋  内蒙古自治区人民医院

Inflammatory fire in the airway activated by respiratory infection in AECOPD

Mengyuan Dai 戴梦缘  安徽医科大学第一附属医院呼吸内科

Early recognition of aspiration after recent general anesthesia and surgery to improve the lung pathology and reduce the duration of intubation and invasion ventilation: a pilot study

Zhenyu Dai  戴震宇  温州医科大学附属第一医院


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1669253, encodeId=d9e4166925391, content=<a href='/topic/show?id=b9a21009271' target=_blank style='color:#2F92EE;'>#ISRD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10092, encryptionId=b9a21009271, topicName=ISRD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ecdd26540939, createdName=skhzy, createdTime=Thu May 18 03:56:00 CST 2017, time=2017-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068217, encodeId=4863206821e6e, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Mon May 15 18:56:00 CST 2017, time=2017-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028358, encodeId=265e2028358ab, content=<a href='/topic/show?id=28ba9899e00' target=_blank style='color:#2F92EE;'>#青年医师#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98997, encryptionId=28ba9899e00, topicName=青年医师)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37d0457, createdName=yhj-time, createdTime=Tue Jul 11 01:56:00 CST 2017, time=2017-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151244, encodeId=84871512448d, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Wed Oct 26 06:46:57 CST 2016, time=2016-10-26, status=1, ipAttribution=)]
    2017-05-18 skhzy
  2. [GetPortalCommentsPageByObjectIdResponse(id=1669253, encodeId=d9e4166925391, content=<a href='/topic/show?id=b9a21009271' target=_blank style='color:#2F92EE;'>#ISRD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10092, encryptionId=b9a21009271, topicName=ISRD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ecdd26540939, createdName=skhzy, createdTime=Thu May 18 03:56:00 CST 2017, time=2017-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068217, encodeId=4863206821e6e, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Mon May 15 18:56:00 CST 2017, time=2017-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028358, encodeId=265e2028358ab, content=<a href='/topic/show?id=28ba9899e00' target=_blank style='color:#2F92EE;'>#青年医师#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98997, encryptionId=28ba9899e00, topicName=青年医师)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37d0457, createdName=yhj-time, createdTime=Tue Jul 11 01:56:00 CST 2017, time=2017-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151244, encodeId=84871512448d, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Wed Oct 26 06:46:57 CST 2016, time=2016-10-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1669253, encodeId=d9e4166925391, content=<a href='/topic/show?id=b9a21009271' target=_blank style='color:#2F92EE;'>#ISRD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10092, encryptionId=b9a21009271, topicName=ISRD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ecdd26540939, createdName=skhzy, createdTime=Thu May 18 03:56:00 CST 2017, time=2017-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068217, encodeId=4863206821e6e, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Mon May 15 18:56:00 CST 2017, time=2017-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028358, encodeId=265e2028358ab, content=<a href='/topic/show?id=28ba9899e00' target=_blank style='color:#2F92EE;'>#青年医师#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98997, encryptionId=28ba9899e00, topicName=青年医师)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37d0457, createdName=yhj-time, createdTime=Tue Jul 11 01:56:00 CST 2017, time=2017-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151244, encodeId=84871512448d, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Wed Oct 26 06:46:57 CST 2016, time=2016-10-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1669253, encodeId=d9e4166925391, content=<a href='/topic/show?id=b9a21009271' target=_blank style='color:#2F92EE;'>#ISRD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10092, encryptionId=b9a21009271, topicName=ISRD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ecdd26540939, createdName=skhzy, createdTime=Thu May 18 03:56:00 CST 2017, time=2017-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068217, encodeId=4863206821e6e, content=<a href='/topic/show?id=e94b298327' target=_blank style='color:#2F92EE;'>#ATS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2983, encryptionId=e94b298327, topicName=ATS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Mon May 15 18:56:00 CST 2017, time=2017-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028358, encodeId=265e2028358ab, content=<a href='/topic/show?id=28ba9899e00' target=_blank style='color:#2F92EE;'>#青年医师#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98997, encryptionId=28ba9899e00, topicName=青年医师)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=37d0457, createdName=yhj-time, createdTime=Tue Jul 11 01:56:00 CST 2017, time=2017-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151244, encodeId=84871512448d, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Wed Oct 26 06:46:57 CST 2016, time=2016-10-26, status=1, ipAttribution=)]
    2016-10-26 忠诚向上

    好好学习

    0

相关资讯

ISRD & ATS 2016:金美玲教授谈真正的哮喘控制意味着什么

金秋十月,满载硕果。第十二届国际呼吸学会暨ATS呼吸论坛在上海展览中心隆重举行。16日上午来自复旦大学上海中山医院的金美玲教授为我们带来了精彩的演讲,她演讲的主题是“真正的哮喘控制意味着什么?”梅斯小编对演讲进行了整理,与大家分享。

ISRD & ATS 2016:白冲教授谈早期肺癌的全程管理

2016 年10月14日~16日,由上海梅斯医学承办的“第十二届上海国际呼吸学会暨ATS联合论坛”(ISRD & ATS 2016)在上海展览中心隆重举行。16日下午,在肺癌专场,来自第二军医大学长海医院呼吸与危重症医学科的白冲教授给我们分享了早期肺癌的全程管理方面的经验。下面是梅斯小编整理的现场精彩报告。

2016年第12届国际呼吸学会暨ATS联合论坛隆重举行

2016年10月14日~16日,由中国健康促进基金会、上海市呼吸病研究所、国际呼吸学会等主办,美国胸科协会(ATS)和复旦大学呼吸病研究所等协办,上海梅斯医学承办的“第十二届上海国际呼吸学会暨ATS联合论坛”(ISRD & ATS 2016)在上海展览中心隆重举行。